Who
Thomas Andrew Rowland
SVP, Head - Established Brands
Company insider
Files Form 4 as: SVP, Head - Established Brands, ANI Pharmaceuticals; Chief Business Officer, Assembly Biosciences.
In numbers
- Trades disclosed
- 22
- Buys
- 0
- Sells
- 3
- Bought
- $0
- Sold
- $1.2M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 25 Jan 2011
- Last trade
- 12 May 2026
- Last filed
- 13 May 2026
Companies traded
Activity over time
1 Aug 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 May 2026filed 13 May 2026 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $36K459 at $79.21 | filing |
| 12 May 2026filed 13 May 2026 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $36K459 at $79.21 | filing |
| 11 Mar 2026filed 13 Mar 2026 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $357K4,772 at $74.91 | filing |
| 11 Mar 2026filed 13 Mar 2026 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $357K4,772 at $74.91 | filing |
| 28 Feb 2026filed 2 Mar 2026 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $46K628 at $73.90 | filing |
| 28 Feb 2026filed 2 Mar 2026 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $46K628 at $73.90 | filing |
| 26 Feb 2026filed 2 Mar 2026 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | $465K6,021 at $77.15 | filing |
| 26 Feb 2026filed 2 Mar 2026 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | $465K6,021 at $77.15 | filing |
| 14 Feb 2026filed 17 Feb 2026 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $38K485 at $77.36 | filing |
| 14 Feb 2026filed 17 Feb 2026 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $38K485 at $77.36 | filing |
| 12 Feb 2026filed 17 Feb 2026 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $43K566 at $76.70 | filing |
| 12 Feb 2026filed 17 Feb 2026 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $43K566 at $76.70 | filing |
| 11 Feb 2026filed 13 Feb 2026 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $134K1,762 at $76.25 | filing |
| 11 Feb 2026filed 13 Feb 2026 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $134K1,762 at $76.25 | filing |
| 12 Aug 2025filed 14 Aug 2025 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $426K4,975 at $85.71 | filing |
| 28 Feb 2025filed 4 Mar 2025 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $39K627 at $61.89 | filing |
| 14 Feb 2025filed 18 Feb 2025 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $34K582 at $58.92 | filing |
| 12 Feb 2025filed 18 Feb 2025 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —7,834 at $0.00 | filing |
| 12 Feb 2025filed 18 Feb 2025 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —5,222 at $0.00 | filing |
| 15 Nov 2024filed 18 Nov 2024 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $49K867 at $56.58 | filing |
News
No headline names them, or the companies they trade most, lately.